WallStreetZenWallStreetZen

NYSE: GKOS
Glaukos Corp Stock

Overview
ForecastEarningsRevenueDividendOwnership
$92.61+2.88 (+3.21%)
Updated Apr 23, 2025
GKOS Price
$92.61
Fair Value Price
N/A
Market Cap
$5.24B
52 Week Low
$77.91
52 Week High
$163.71
P/E
-33.43x
P/B
6.83x
P/S
20.63x
PEG
N/A
Dividend Yield
N/A
Revenue
$383.48M
Earnings
-$146.37M
Gross Margin
75.5%
Operating Margin
-35.35%
Profit Margin
-38.2%
Debt to Equity
0.27
Operating Cash Flow
-$61M
Beta
1.22
Next Earnings
Apr 29, 2025
Ex-Dividend
N/A
Next Dividend
N/A

GKOS Overview

Glaukos Corporation is an ophthalmic technology and pharmaceutical company developing novel therapies to treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, and iStent inject W micro-bypass stents that enhance aqueous humor outflow and are inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Glaukos was incorporated in 1998 and is headquartered in San Clemente, CA.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine GKOS's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
View All “A” Zen Rated Stocks
→

Zen Rating Component Grades

C
Value
A
Growth
D
Momentum
C
Sentiment
C
Safety
C
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical Device

Industry Rating
C
GKOS
Ranked#56 of 104

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
Bioventus (BVS)
$7.59A
Electromed (ELMD)
$22.81A
Tactile Systems Technology (TCMD)
$14.03A
View Top Medical Device Stocks

Be the first to know about important GKOS news, forecast changes, insider trades & much more!

GKOS News

Overview

Due Diligence Score

–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GKOS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

GKOS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GKOS is poor value based on its book value relative to its share price (6.83x), compared to the US Medical Devices industry average (3.85x)
P/B vs Industry Valuation
GKOS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more GKOS due diligence checks available for Premium users.

Valuation

GKOS price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-33.43x
Industry
35.78x
Market
26.95x

GKOS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
6.83x
Industry
3.85x
GKOS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

GKOS's financial health

Profit margin

Revenue
$105.5M
Net Income
-$33.6M
Profit Margin
-31.8%
GKOS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
GKOS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$974.8M
Liabilities
$207.8M
Debt to equity
0.27
GKOS's short-term assets ($449.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GKOS's short-term assets ($449.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GKOS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GKOS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$507.0k
Investing
$11.8M
Financing
$60.1M
GKOS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

GKOS vs Medical Device Stocks

TickerZen RatingMarket Cap1d %P/EP/B
GKOSC$5.24B+3.21%-33.43x6.83x
BRKRC$5.75B+2.52%49.86x3.23x
INSPB$4.40B-0.23%82.43x6.38x
ITGRC$4.05B+2.14%33.76x2.50x
BIOC$6.97B+1.58%-3.81x1.06x
View Top Medical Device Stocks

Glaukos Stock FAQ

What is Glaukos's quote symbol?

(NYSE: GKOS) Glaukos trades on the NYSE under the ticker symbol GKOS. Glaukos stock quotes can also be displayed as NYSE: GKOS.

If you're new to stock investing, here's how to buy Glaukos stock.

What is the 52 week high and low for Glaukos (NYSE: GKOS)?

(NYSE: GKOS) Glaukos's 52-week high was $163.71, and its 52-week low was $77.91. It is currently -43.43% from its 52-week high and 18.87% from its 52-week low.

How much is Glaukos stock worth today?

(NYSE: GKOS) Glaukos currently has 56,567,386 outstanding shares. With Glaukos stock trading at $92.61 per share, the total value of Glaukos stock (market capitalization) is $5.24B.

Glaukos stock was originally listed at a price of $31.22 in Jun 25, 2015. If you had invested in Glaukos stock at $31.22, your return over the last 9 years would have been 196.64%, for an annualized return of 12.84% (not including any dividends or dividend reinvestments).

How much is Glaukos's stock price per share?

(NYSE: GKOS) Glaukos stock price per share is $92.61 today (as of Apr 23, 2025).

What is Glaukos's Market Cap?

(NYSE: GKOS) Glaukos's market cap is $5.24B, as of Apr 24, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Glaukos's market cap is calculated by multiplying GKOS's current stock price of $92.61 by GKOS's total outstanding shares of 56,567,386.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.